Company Information

KREBS BIOCHEMICALS & INDUSTRIES LTD.

NSE : KREBSBIOBSE : 524518ISIN CODE : INE268B01013Industry : Pharmaceuticals & DrugsHouse : Private
BSE73.011.86 (+2.61 %)
PREV CLOSE ( ) 71.15
OPEN PRICE ( ) 72.75
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 265
TODAY'S LOW / HIGH ( )72.35 73.85
52 WK LOW / HIGH ( )59.3 93.2
NSE73.001.45 (+2.03 %)
PREV CLOSE( ) 71.55
OPEN PRICE ( ) 71.00
BID PRICE (QTY) 73.00 (41)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 3926
TODAY'S LOW / HIGH( ) 71.00 74.00
52 WK LOW / HIGH ( )59.2 93.95
ChairmanR T Ravi
Managing DirectorJitendra Shah
Non Executive Independent DirectorGVL Prasad
Raj Kamal Prasad Verma
Tangirala Malati
Satish Khivsara
Non Independent & Non Executive DirectorAvinash Ravi
Pabitrakumar Kalipada Bhattacharyya
Incorporation Year : 02-12 1991

Registered Office :

Address : Kothapalli Village,Anakapalli,Kasimkota Mandal Vishakhapatnam,
Andhra Pradesh-531031 .

Phone : 040-66808040 / 9121144984

Industry : Pharmaceuticals & Drugs

Listing : BSE,NSE

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.